Wednesday, September 23, 2015

Free Market Movement

Days after Turing Founder Martin Shkreli defended his  position for raising the price of Daraprim to $750 the company is now make more changes.
Early this week, Turing’s decision to raise the price of Daraprim from $13.50 a tablet to $750 was the subject of a New York Times story. The drug, which is generically known as pyrimethamine and was acquired by the company acquired in August, is used to treat a serious parasitic infection called toxoplasmosis, which can be life-threatening for those with compromised immune systems. 
Shkreli said the new price will allow the company to break even or make a “small profit” on the drug. - Fortune
Government intervention not required.

#Daraprim  #PrescriptionDrugs
blog comments powered by Disqus